Satellos Bioscience Valuation
| MSCL Stock | 15.99 0.52 3.36% |
At this time, the company appears to be overvalued. Satellos Bioscience has a current Real Value of USD11.73 per share. The regular price of the company is USD15.99. Our model measures the value of Satellos Bioscience from inspecting the company fundamentals such as Return On Equity of -0.88, price to book of 5.06 X, and Shares Outstanding of 15.46 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Satellos Bioscience's valuation include:
Overvalued
Today
Please note that Satellos Bioscience's price fluctuation is somewhat reliable at this time. Calculation of the real value of Satellos Bioscience is based on 3 months time horizon. Increasing Satellos Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Satellos Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Satellos Stock. However, Satellos Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.99 | Real 11.73 | Hype 15.99 | Naive 16.84 |
The intrinsic value of Satellos Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Satellos Bioscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Satellos Bioscience helps investors to forecast how Satellos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Satellos Bioscience more accurately as focusing exclusively on Satellos Bioscience's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Satellos Bioscience's intrinsic value based on its ongoing forecasts of Satellos Bioscience's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Satellos Bioscience's closest peers.
Satellos Bioscience Cash |
|
Satellos Bioscience Total Value Analysis
Satellos Bioscience is now estimated to have takeover price of 186.87 M with market capitalization of 239.15 M, debt of 5.16 M, and cash on hands of 40.07 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Satellos Bioscience fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
186.87 M | 239.15 M | 5.16 M | 40.07 M |
Satellos Bioscience Asset Utilization
One of the ways to look at asset utilization of Satellos is to check how much profit was generated for every dollar of assets it reports. Satellos Bioscience has a negative utilization of assets of -0.54 %, losing USD0.005425 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Satellos Bioscience shows how discouraging it operates for each dollar spent on its assets.Satellos Bioscience Profitability Analysis
Based on the measurements of profitability obtained from Satellos Bioscience's financial statements, Satellos Bioscience may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Satellos Bioscience's ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -25.3 M | Current Value -24 M | Quarterly Volatility 9.7 M |
For Satellos Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Satellos Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Satellos Bioscience utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Satellos Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Satellos Bioscience over time as well as its relative position and ranking within its peers.
Satellos Bioscience Earnings per Share Projection vs Actual
By analyzing Satellos Bioscience's earnings estimates, investors can diagnose different trends across Satellos Bioscience's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Satellos Bioscience is based on EPS before non-recurring items and includes expenses related to employee stock options.Satellos Bioscience Ownership Allocation
Satellos Bioscience shows a total of 15.46 Million outstanding shares. Satellos Bioscience has 8.3 % of its outstanding shares held by insiders and 8.2 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Satellos Bioscience Profitability Analysis
Net Loss for the year was (28.1 M) with loss before overhead, payroll, taxes, and interest of (16.68 M).About Satellos Bioscience Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Satellos Bioscience. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Satellos Bioscience based exclusively on its fundamental and basic technical indicators. By analyzing Satellos Bioscience's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Satellos Bioscience's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Satellos Bioscience. We calculate exposure to Satellos Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Satellos Bioscience's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -18 K | -18.9 K |
Other Information on Investing in Satellos Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.